Effect of psoriasis activity on serum adiponectin and leptin levels

Postepy Dermatologii i Alergologii

Volumn 32, Issue 2, 2015, Pages 101-106

  Baran, Anna ^a   Flisiak, Iwona ^a   Jaroszewicz, Jerzy ^a   ͆widerska, Magdalena ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Adipokines; Adiponectin; Leptin; Psoriasis; Psoriasis severity

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; LEPTIN;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HOSPITALIZATION; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MALE; OBESITY; PROTEIN BLOOD LEVEL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RELAPSE; RISK ASSESSMENT; THROMBOCYTE COUNT;

EID: 84927721902     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: 10.5114/pdia.2014.40960     Document Type: Article

References (44)

1. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
2. Green L. An overview and update of psoriasis. Nurs Stand 2011; 25: 47-55.
3. Gudjonsson J, Elder J. Psoriasis: epidemiology. Clin Dermatol 2007; 25: 535-46.
4. Liu Y, Krueger J, Bowcock A. Psoriasis: genetic associations and immune system changes. Genes Immun 2007; 8: 1-12.
5. Ryan S. Psoriasis: characteristics, psychosocial effects and treatment options. Br J Nurs 2010; 19: 820, 822-5.
6. Nedoszytko B, Sokołowska-Wojdyło M, Ruckemann-Dziurdzińska K, et al. Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis. Postep Derm Alergol 2014; 31: 84-91.
7. Chomiczewska-Skóra D, Trznadel-Grodzka E, Rotsztejn H. Psoriasis as a disease associated with the immune system disorders. Centr Eur J Immunol 2013; 38: 129-33.
8. Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol Veneorol 2011; 146: 9-15.
9. Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg 2010; 29: 10-5.
10. Wielowieyska-Szybińska D, Wojas-Pelc A. Psoriasis: course of disease and treatment. Postep Derm Alergol 2012; 29: 118-22.
11. Ahlehoff O, Gislason GH, Lindhardsen J, et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One 2011; 25: e18125.
12. Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144:1571-5.
13. Love TJ, Qureshi AA, Karlson EW, et al. Prevalence of metabolic syndrome in psoriasis. Results from the national health and nutrition examination survey, 2003-2006. Arch Dermatol 2011; 147: 419-24.
14. Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol 2011; 20: 81-7.
15. Herron MD, Hinckley M, Hoffman MS, et al. The impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-34.
16. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressfull life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-7.
17. Gerdes S, Osadtschy S, Rostami-Yazdi M, et al. Leptin, adiponectin, visfatin and retinol-binding protein-4- mediators of comorbidities in patients with psoriasis? Exp Dermatol 2012; 21: 43-7.
18. Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97.
19. Wozniak SE, Gee LL, Wachtel MS, et al. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009; 54: 1847-56.
20. Kaur S, Zilmer K, Kairane C, et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008; 159: 1364-7.
21. Kaur S, Zilmer K, Leping V, et al. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. J Eur Acad Dermatol Venereol 2011; 25: 1328-33.
22. Shibata S, Tada Y, Hau C, et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol 2011; 164: 667-70.
23. Flisiak I, Zaniewski P, Rogalska M, et al. Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine 2010; 52: 225-9.
24. Raucci R, Rusolo F, Sharma A, et al. Functional and structural features of adipokine family. Cytokine 2013; 61: 1-14.
25. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24-30.
26. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin-the classical, resistin-the controversial, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19: 525-46.
27. Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008; 159: 342-50.
28. Conde J, Scotece M, Gómez R, et al. At the crossroad between immunity and metabolism: focus on leptin. Expert Rev Clin Immunol 2010; 6: 801-8.
29. Cerman AA, Bozkurt S, Sav A, et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008; 159: 820-6.
30. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
31. Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 1386-94.
32. Janusz I, Lewandowski K, Lukamowicz J, et al. Assessment of insulin resistance and adiponectin concentration in patients with psoriasis vulgaris. Postep Derm Alergol 2010; 27: 451-5.
33. Nakajima H, Nakajima K, Tarutani M, et al. Kinetics of circulating cytokines and adipokines in psoriasis patients. Arch Dermatol Res 2011; 303: 451-5.
34. Stępień M, Wlazeł RN, Paradowski M, et al. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients - pilot study. Arch Med Sci 2012; 8: 431-6.
35. Ozdemir M, Yüksel M, Gökbel H, et al. Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporine. J Dermatol 2012; 39: 443-8.
36. Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr 2014; 105: 31-44.
37. Shibata S, Saeki H, Tada Y, et al. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009; 55: 62-3.
38. Peters MJ, Watt P, Cherry L, et al. Lack of effect of TNFalpha blockade on circulating adiponectin levels in patients with autoimmune disease results from two independent prospective studies. Ann Rheum Dis 2010; 69: 1687-90.
39. Abdel Hay RM, Rashed LA. Association between the leptin gene 2548G/A polymorphism, the plasma leptin and the metabolic syndrome with psoriasis. Exp Dermatol 2011; 20: 715-9.
40. Nakajima H, Nakajima K, Nagano Y, et al. Circulating level of chemerin is upregulated in psoriasis. J Dermatol Sci 2010; 60: 45-7.
41. Wang Y, Chen J, Zhao Y, et al. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008; 158: 1134-5.
42. Kawashima K, Torii K, Furuhashi T, et al. Phototherapy reduces serum resistin levels in psoriasis patients. Photodermatol Photoimmunol Photomed 2011; 27: 152-5.
43. Takahashi H, Tsuji H, Takahashi I, et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008; 159: 1207-8.
44. Bik W. The relationship between secretion of adipokines or insulin resistance and association of selected genes' polymorphisms of adiponectin and resistinin obesity. Post N Med 2009; 12: 912-80.